Article
Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana.
Journal of global antimicrobial resistance - 1 Dec 2022
Bareng Ontlametse T, Seselamarumo Sekgabo, Seatla Kaelo K, Choga Wonderful T, Bakae Blessing, Maruapula Dorcas, Kelentse Nametso, Moraka Natasha O, Mokaleng Baitshepi, Mokgethi Patrick T, Ditlhako Tsotlhe R, Pretorius-Holme Molly, Mbulawa Mpaphi B, Lebelonyane Refeletswe, Bile Ebi Celestin, Gaolathe Tendani, Shapiro Roger, Makhema Joseph M, Lockman Shahin, Essex Max, Novitsky Vlad, Mpoloka Sununguko W, Moyo Sikhulile, Gaseitsiwe Simani
Abstract excerpt
OBJECTIVES: There are limited data on the prevalence of doravirine (DOR)-associated drug resistance mutations in people with HIV (PWH) in Botswana. This cross-sectional, retrospective study aimed to explore the prevalence of DOR-associated resistance mutations among ART-naïve and -experienced PWH in Botswana enrolled in the population-based Botswana Combination Prevention Project (BCPP). METHODS: A total of 6078...
Topics
Join the communities discussing this publication.
